Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US-9096651-B2 · Aug 4, 2015 · US
Antibody constant region variant
US9228017B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9228017-B2 |
| Application number | US-201013257112-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 19, 2010 |
| Priority date | Mar 19, 2009 |
| Publication date | Jan 5, 2016 |
| Grant date | Jan 5, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
By altering amino acid sequence, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated.
First claim
Opening claim text (preview).
The invention claimed is: 1. An antibody constant region comprising the amino acid sequence of SEQ ID NO: 8 with only the following changes: Cys at position 102 (position 219 (EU numbering)) and Cys at position 103 (position 220 (EU numbering)) are both substituted with Ser; and, optionally, His at position 147 (position 268 (EU numbering)) is substituted with Gln, Arg at position 234 (position 355 (EU numbering)) is substituted with Gln, and Gln at position 298 (position 419 (EU numbering)) is substituted with Glu; and, optionally, Gly at position 325 (position 446 (EU numbering)) and Lys at position 326 (position 447 (EU numbering)) are deleted. 2. The antibody constant region of claim 1 , wherein His at position 147 is substituted with Gln, Arg at position 234 is substituted with Gln, and Gln at position 298 is substituted with Glu. 3. The antibody constant region of claim 1 , comprising deletions of Gly at position 325 (position 446 (EU numbering)) and Lys at position 326 (position 447 (EU numbering)). 4. The antibody constant region of claim 2 , comprising deletions of Gly at position 325 (position 446 (EU numbering)) and Lys at position 326 (position 447 (EU numbering)). 5. An antibody comprising the constant region of claim 1 . 6. A pharmaceutical composition comprising the antibody of claim 5 . 7. An antibody comprising the constant region of claim 2 . 8. A pharmaceutical composition comprising the antibody of claim 7 . 9. An antibody comprising the constant region of claim 3 . 10. A pharmaceutical composition comprising the antibody of claim 9 . 11. An antibody comprising the constant region of claim 4 . 12. A pharmaceutical composition comprising the antibody of claim 11 .
Assignees
Inventors
Classifications
characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin · CPC title
Constant or Fc region; Isotype · CPC title
CH3 domain · CPC title
CH1 domain · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9228017B2 cover?
- By altering amino acid sequence, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level b…
- Who is the assignee on this patent?
- Igawa Tomoyuki, Maeda Atsuhiko, Shiraiwa Hirotake, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2866. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).